Changes between two versions
What changed between the resolution motion and the adopted text
From · resolution motion· 23 Oct 2024
on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified cotton COT102 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council
AI:What changed, in short
The resolution now calls for repeal of the adopted decision instead of withdrawal of the draft.4 Other changes are formal: corrected agency name and updated references to the decision.123
1 change of substance · 3 formal · 0 of wording only
Written by AI from the two texts only · read the changes before relying on it · 4 Sept 2026 · Report a problem
Changes to the text itself, in document order. Cover page, citations and punctuation-only edits are left out; they are under “Every difference”.
Changes of substance · 1
Change 4 Substance
AI summary:Changes the request from withdrawing the draft decision to repealing the adopted Implementing Decision (EU) 2024/2627.
Show the text change (1 line)
Changed:3. Calls on the Commission to withdrawrepeal itsImplementing draftDecision implementing(EU) decision2024/2627 and to submit a new draft to the committee;
3 formal changes: legal basis, citations, references, corrections
Change 1 Formal
AI summary:Corrects the name of the European Medicines Agency and updates the reference to the implementing decision.
Show the text change (1 line)
Changed:P. whereas the European MedicineMedicines Agency has confirmed there are no products containing hygromycin B authorised for therapeutic, prophylactic or any other medical uses in humans or animals in the Member States and there are no central authorisations for human or veterinary use for medicinal products that contain hygromycin B11; whereas the EFSA opinion states that ‘the GMO Panel considers that the risk assessment may need to be updated in case products containing hygromycin B or other substrates of the APH4 enzyme obtain future market approval in the EU’; whereas, however, hygromycin B is used in veterinary products which are sold outside the Union;
Change 2 Formal
AI summary:Replaces the reference to the draft Commission implementing decision with the adopted Implementing Decision (EU) 2024/2627.
Show the text change (1 line)
Changed:1. Considers that the draftImplementing CommissionDecision implementing(EU) decision2024/2627 exceeds the implementing powers provided for in Regulation (EC) No 1829/2003;
Change 3 Formal
AI summary:Replaces the reference to the draft Commission implementing decision with the adopted Implementing Decision (EU) 2024/2627.
Show the text change (1 line)
Changed:2. Considers that the draftImplementing CommissionDecision implementing(EU) decision2024/2627 is not consistent with Union law, in that it is not compatible with the aim of Regulation (EC) No 1829/2003, which is, in accordance with the general principles laid down in Regulation (EC) No 178/2002 of the European Parliament and of the Council, to provide the basis for ensuring a high level of protection of human life and health, animal health and welfare, and environmental and consumer interests, in relation to GM food and feed, while ensuring the effective functioning of the internal market;